DNA Life Sciences Limited 14412352 false 2022-10-11 2023-12-31 2023-12-31 The principal activity of the company is that of a recruitment services Digita Accounts Production Advanced 6.30.9574.0 true false true 14412352 2022-10-11 2023-12-31 14412352 2023-12-31 14412352 bus:OrdinaryShareClass1 2023-12-31 14412352 core:CurrentFinancialInstruments 2023-12-31 14412352 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 14412352 bus:SmallEntities 2022-10-11 2023-12-31 14412352 bus:Audited 2022-10-11 2023-12-31 14412352 bus:FilletedAccounts 2022-10-11 2023-12-31 14412352 bus:SmallCompaniesRegimeForAccounts 2022-10-11 2023-12-31 14412352 bus:RegisteredOffice 2022-10-11 2023-12-31 14412352 bus:Director1 2022-10-11 2023-12-31 14412352 bus:OrdinaryShareClass1 2022-10-11 2023-12-31 14412352 bus:PrivateLimitedCompanyLtd 2022-10-11 2023-12-31 14412352 bus:Agent1 2022-10-11 2023-12-31 14412352 core:OtherRelatedParties 2022-10-11 2023-12-31 14412352 1 2022-10-11 2023-12-31 14412352 countries:AllCountries 2022-10-11 2023-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registrar

Registration number: 14412352

DNA Life Sciences Limited

Filleted Financial Statements

for the Period from 11 October 2022 to 31 December 2023

 

DNA Life Sciences Limited

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 6

 

DNA Life Sciences Limited

Company Information

Directors

L A C Silvester

Registered office

3 Warners Mill
Silks Way
Braintree
Essex
CM7 3GB

Bankers

Lloyds Bank Plc
West Bromwich
293 High Street
West Bromwich
West Midlands
B70 8NA

Auditors

Lambert Chapman LLP
Chartered Accountants & Statutory Auditors
3 Warners Mill
Silks Way
Braintree
Essex
CM7 3GB

 

DNA Life Sciences Limited

(Registration number: 14412352)
Balance Sheet as at 31 December 2023

Note

2023
£

Current assets

 

Debtors

4

122,470

Cash at bank and in hand

 

1,545

 

124,015

Creditors: Amounts falling due within one year

5

(661,291)

Net liabilities

 

(537,276)

Capital and reserves

 

Called up share capital

6

1,000

Retained earnings

(538,276)

Shareholders' deficit

 

(537,276)

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 28 October 2024
 

L A C Silvester
Director

 

DNA Life Sciences Limited

Notes to the Financial Statements for the Period from 11 October 2022 to 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is: 3 Warners Mill, Silks Way, Braintree, Essex, CM7 3GB.

The principal place of business is: 150 The Minories, London, EC3N 1LS.

These financial statements were authorised for issue by the director on 28 October 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention.

These financial statements are presented in Sterling (£), which is the company's functional currency.

Audit report

The Independent Auditor's Report was unqualified.

We draw attention to the note below, which describes the current trading status of the company and considerations in relation to going concern. Our opinion is not modified in respect of this matter.

The name of the Senior Statutory Auditor who signed the audit report on 28 October 2024 was Graham McNeill FCCA, who signed for and on behalf of Lambert Chapman LLP.

Going concern

The director has considered the availability of resources to meet the company’s liabilities to 31 December 2025. The director has considered the going concern position of the company, taking into account the performance of the 2023 year, the actual results to August 2024 and the forecasts up to December 2025. As part of this going concern review, the director has prepared and undertaken a comprehensive review of the forecasts covering a period through to 31 December 2025 which demonstrates that the company will continue to have sufficient cash availability and profitability to continue as a going concern.

The director and connected entities including the new parent company, Envious Holdings Inc. and its ultimate shareholder are committed to providing the necessary funds as required.

 

DNA Life Sciences Limited

Notes to the Financial Statements for the Period from 11 October 2022 to 31 December 2023

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the placement of permanent and temporary staff in the ordinary course of the companies' activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
-the amount of revenue can be reliably measured.
-it is probable that future economic benefit will flow to the entity.
-and specific criteria have been met for each of the company's entities.

Turnover from temporary placements represents the fees billed for the services performed including their costs and is recognised when the service has been provided.

Turnover from permanent placements is recognised based upon either the candidate's start date or the date of the candidate's acceptance of a position in accordance with the terms of business.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. All exchange rate variances are recognised in the profit and loss account.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised on material temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits.

Trade debtors

Trade debtors are amounts due from customers for recruitment services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Trade creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

 

DNA Life Sciences Limited

Notes to the Financial Statements for the Period from 11 October 2022 to 31 December 2023

Share capital

Ordinary shares are classified as equity.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including the director) during the period, was 5.

4

Debtors

2023
£

Trade debtors

73,634

Other debtors

33,490

Prepayments and accrued income

15,346

122,470

5

Creditors

Creditors: amounts falling due within one year

2023
£

Due within one year

Trade creditors

103,878

Other creditors

491,055

Taxation and social security

59,858

Accruals and deferred income

6,500

661,291

6

Share capital

Allotted, called up and fully paid shares

2023

No.

£

Ordinary shares of £1 each

1,000

1,000

   
 

DNA Life Sciences Limited

Notes to the Financial Statements for the Period from 11 October 2022 to 31 December 2023

7

Related party transactions

Summary of transactions with other related parties

At the balance sheet date, the company owed amounts totalling £479,404 to entities under common control.
 

8

Parent and ultimate parent undertaking

The company's immediate parent is Envious Holdings Inc, incorporated in The United States of America.

 The ultimate controlling party is S H Jones.